-
A607321-10mgABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain.
-
A607321-1mgABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain.
-
A607321-25mgABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain.
-
A607321-50mgABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain.
-
A607321-5mgABBV-318 is a potent Nav1.7/ Nav1.8 blocker, with IC50s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8, respectively. ABBV-318 can be used for the research of pain.
-
-
-
A414135-100mgInformationABBV-744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.TargetsBDIIIn vitroABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with
-
A414135-10mgInformationABBV-744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.TargetsBDIIIn vitroABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with
-
A414135-25mgInformationABBV-744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.TargetsBDIIIn vitroABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with
-
A414135-2mgInformationABBV-744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.TargetsBDIIIn vitroABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with
-
A414135-50mgInformationABBV-744 ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.TargetsBDIIIn vitroABBV-744 is a potent inhibitor specific for BDII of BRD2/3/4, with